Immunomodulating compounds and related compositions and methods

Abstract

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

1 . A method to balance a T-helper cell profile in an individual, the method comprising administering to the individual an effective amount of a zwitterionic polysaccharide. 
     
     
         2 . The method of  claim 1 , wherein the T-helper cell is a subset of T-helper cells, the subset consisting of at least one of Th1, Th2, Th17, and Treg. 
     
     
         3 . The method of  claim 1 , wherein the T-helper cell is a subset of T-helper cells, the subset consisting of Th17 and at least one of Th1, Th2, and Treg. 
     
     
         4 . The method of  claim 1 , wherein the T-helper cell is Th17. 
     
     
         5 . The method of  claim 1 , wherein the zwitterionic polysaccharide is a naturally occurring bacterial capsular polysaccharide. 
     
     
         6 . The method of  claim 1 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA) or polysaccharide B (PSB). 
     
     
         7 . The method of  claim 1 , wherein the effective amount is in a range from about 1 μg to about 100 μg of zwitterionic polysaccharide per 0.025 kilograms of body weight. 
     
     
         8 . The method of  claim 1 , wherein the effective amount is in a range from about 0.001 μg to about 1,000 μg per 0.25 kilograms of body weight. 
     
     
         9 . A method to control an inflammation associated with an imbalance of a T-helper cell profile in an individual, the method comprising administering to the individual an effective amount of a zwitterionic polysaccharide. 
     
     
         10 . The method of  claim 9 , wherein the T-helper cell is Th17. 
     
     
         11 . The method of  claim 9 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA) or polysaccharide B (PSB). 
     
     
         12 . The method of  claim 9 , wherein the method is a therapeutic method for treating the cytokine mediated inflammation and the effective amount of PSA is a therapeutically effective amount of a zwitterionic polysaccharide. 
     
     
         13 . A method to control cytokine production in an individual, the cytokine being at least one of IL-1, IL-6, TNF-a, IL-17, IL21, IL23, the method comprising administering to the individual an effective amount of a zwitterionic polysaccharide. 
     
     
         14 . The method of  claim 13 , wherein the cytokine is IL-17. 
     
     
         15 . The method of  claim 13 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA). 
     
     
         16 . A method to control an inflammation associated with production of at least one of IL-1, IL-6, TNF-a, IL-17, IL21, IL23 in an individual, the method comprising administering to the individual an effective amount of a zwitterionic polysaccharide. 
     
     
         17 . The method of  claim 16 , wherein the method is a therapeutic method for treating the inflammation and the effective amount of zwitterionic polysaccharide is a therapeutically effective amount of zwitterionic polysaccharide. 
     
     
         18 . An anti-inflammatory composition comprising a zwitterionic polysaccharide and a suitable vehicle, wherein the zwitterionic polysaccharide is comprised in an amount of from about 1 μg to about 100 μg. 
     
     
         19 . The anti-inflammatory composition of  claim 18 , wherein the zwitterionic polysaccharide is comprised in an amount of from about 0.01 μg to about 1,000 μg. 
     
     
         20 . The anti-inflammatory composition of  claim 18 , wherein the composition is a pharmaceutical composition and wherein the suitable vehicle is a pharmaceutically acceptable vehicle. 
     
     
         21 . The anti-inflammatory composition of  claim 18 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA) or polysaccharide B (PSB).